Discretionary transaction by Martin Lehr of 52680 shares of Context Therapeutics at 7.14 subject to Rule 16b-3

CNTX Stock  USD 1.56  0.04  2.63%   
Slightly above 72 percent of all Context Therapeutics' investors are curious in acquiring. The analysis of overall sentiment of trading Context Therapeutics stock suggests that a large number of investors are confidant at this time. Context Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Context Therapeutics' earnings reports, geopolitical events, and overall market trends.
  
Filed transaction by Context Therapeutics Director, Officer Chief Executive Officer. Discretionary transaction in accordance with Rule 16b-3

Read at macroaxis.com
Transaction of 52680 warrant (right to buy) at 7.14 of Context Therapeutics by Martin Lehr on 9th of October 2024. This event was filed by Context Therapeutics with SEC on 2020-12-20. Initial filing of beneficial ownership - SEC Form 3

Cash Flow Correlation

Context Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Context Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Context Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Context Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Context Therapeutics Fundamental Analysis

We analyze Context Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Context Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Context Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Number Of Shares Shorted

Number Of Shares Shorted Comparative Analysis

Context Therapeutics is currently under evaluation in number of shares shorted category among its peers. Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.

Context Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Context Therapeutics stock to make a market-neutral strategy. Peer analysis of Context Therapeutics could also be used in its relative valuation, which is a method of valuing Context Therapeutics by comparing valuation metrics with similar companies.

Peers

Context Therapeutics Related Equities

INABIn8bio   23.33   
0%
100.0%
CHRSCoherus BioSciences   12.30   
0%
52.0%
ABOSAcumen Pharmaceuticals   3.52   
0%
15.0%
INZYInozyme Pharma   2.95   
0%
12.0%
CTMXCytomX Therapeutics   2.83   
0%
12.0%
WVEWave Life   1.13   
0%
4.0%
AMLXAmylyx Pharmaceuticals   0.18   
0%
1.0%
DAWNDay One   0.65   
2.0%
0%
NXTCNextCure   0.85   
3.0%
0%
SPROSpero Therapeutics   0.88   
3.0%
0%
TERNTerns Pharmaceuticals   1.44   
6.0%
0%
BOLTBolt Biotherapeutics   1.56   
6.0%
0%
ASMBAssembly Biosciences   1.70   
7.0%
0%
ANNXAnnexon   2.23   
9.0%
0%
XFORX4 Pharmaceuticals   5.13   
21.0%
0%
ZURAZura Bio   8.20   
35.0%
0%

Additional Tools for Context Stock Analysis

When running Context Therapeutics' price analysis, check to measure Context Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Context Therapeutics is operating at the current time. Most of Context Therapeutics' value examination focuses on studying past and present price action to predict the probability of Context Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Context Therapeutics' price. Additionally, you may evaluate how the addition of Context Therapeutics to your portfolios can decrease your overall portfolio volatility.